Oculis Holding AG (OCS) stock
OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 4, 2026Score 1/30
$7.39−0.12 (-1.60%)
Close on Nov 18, 2026Market cap $444.06MP/E –Yield –
Oculis r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was CHF 57.09M, up 9.6% from the year before. The highest annual figure on record is CHF 57.09M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 57.09M | +9.6% |
| FY2024 | Dec 31, 2024 | CHF 52.08M | +78.1% |
| FY2023 | Dec 31, 2023 | CHF 29.25M | +31.6% |
| FY2022 | Dec 31, 2022 | CHF 22.22M | +132.3% |
| FY2021 | Dec 31, 2021 | CHF 9.57M | +2.5% |
| FY2020 | Dec 31, 2020 | CHF 9.34M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | CHF 15.28M | – |
| Q2 FY2025 | Jun 30, 2025 | CHF 14.91M | – |
| Q2 FY2024 | Jun 30, 2024 | CHF 16.47M | – |
| Q2 FY2023 | Jun 30, 2023 | CHF 6.20M | – |
See a number that looks wrong?